Holen Sie sich die Stockscreener-App
27.64
5.95%
-1.935
Schlusskurs vom Vortag:
$29.58
Offen:
$27.18
24-Stunden-Volumen:
25,919
Relative Volume:
0.03
Marktkapitalisierung:
$44.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.35M
KGV:
-19.07
EPS:
-1.45
Netto-Cashflow:
$-36.91M
1W Leistung:
+11.39%
1M Leistung:
-4.33%
6M Leistung:
+633.07%
1J Leistung:
+405.82%
1-Tages-Spanne:
$26.73
$28.25
1-Wochen-Bereich:
$22.18
$32.00
52-Wochen-Spanne:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Firmenname
Galecto Inc
Sektor
Branche
Telefon
45-70-70-52-10
Adresse
75 STATE STREET, BOSTON
Vergleichen Sie GLTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
27.82 | 47.33M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.65 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.50 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
824.99 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.60 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.60 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Galecto Inc Aktie (GLTO) Neueste Nachrichten
Fund Flows: Should I set a stop loss on CNFR2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Exit Recap: What is Dow Incs book value per sharePortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Galecto Inc. stock supported by innovation pipelineTechnical Breakout Signals & Maximize Gains Professionally - bollywoodhelpline.com
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Movement Recap: Is Galecto Incs ROIC above industry averageJuly 2025 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Galecto (GLTO) Price Target Increased by 13.89% to 41.82 - Nasdaq
Investment Recap: Can Galecto Inc stock double in next 5 yearsEarnings Recap Report & Safe Entry Point Alerts - Bộ Nội Vụ
Galecto on track to submit IND for mutCALR antibody by mid-2026 - Investing.com Nigeria
Galecto on track to submit IND for mutCALR antibody by mid-2026 By Investing.com - Investing.com India
Galecto (GLTO) Sets Ambitious Clinical Milestones for 2026 - GuruFocus
Galecto Showcases New mutCALR MPN Pipeline at JPM - TipRanks
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
Galecto, Inc. Reports Strategic Shift and Financial Results - MSN
Galecto Completes Acquisition of Damora Therapeutics - MSN
Galecto (NASDAQ:GLTO) Upgraded at Leerink Partnrs - Defense World
What risks investors should watch in Galecto Inc. stock2025 Year in Review & Consistent Growth Equity Picks - ulpravda.ru
Is Galecto Inc. stock attractive for hedge fundsJuly 2025 Breakouts & Daily Price Action Insights - Улправда
Should I hold or sell Galecto Inc. stock in 2025July 2025 Patterns & High Conviction Investment Ideas - ulpravda.ru
Galecto (NASDAQ:GLTO) Now Covered by Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Galecto (GLTO) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Coverage on GLTO with 'Outperform' Ra - GuruFocus
Leerink Partners initiates coverage on Galecto stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners initiates coverage on Galecto stock with Outperform rating - Investing.com
Galecto strengthens its leadership after recent acquisition in the US - medwatch.com
Galecto appoints former Blueprint Medicines executives as COO and CMO - MSN
Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer - marketscreener.com
Galecto appoints new chief operating officer, enhances leadership - TipRanks
Galecto announces key additions to leadership team - marketscreener.com
Galecto appoints Sherwin Sattarzadeh as chief operating officer and issues warrant - Investing.com
Galecto, Inc. Appoints New Chief Operating Officer - TradingView — Track All Markets
Galecto Announces Key Additions to Leadership Team - The Manila Times
Galecto (GLTO) grants large warrant and hires new Chief Operating Officer - Stock Titan
Galecto, Inc. Appoints Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer, Effective January 5, 2026 - marketscreener.com
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Is the Market Bullish or Bearish on Galecto Inc? - Benzinga
Will Galecto Inc stock pay special dividends2025 Historical Comparison & Growth-Oriented Investment Plans - Bộ Nội Vụ
Galecto Files to Register 60.5 Million Shares for Secondary Offering - marketscreener.com
GLTO SEC FilingsGalecto Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Galecto (NASDAQ:GLTO) Shares Down 13.3%Time to Sell? - MarketBeat
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell? - Defense World
[EFFECT] Galecto, Inc. SEC Filing - Stock Titan
Ideas Watch: Should I hold or sell Galecto Inc stock in 2025 - Bộ Nội Vụ
Why Galecto Inc. stock could benefit from AI revolution2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Galecto (GLTO) Price Target Increased by 12.50% to 36.72 - Nasdaq
How Galecto Inc. stock performs after earningsQuarterly Profit Summary & Reliable Breakout Forecasts - Улправда
How rising interest rates impact Galecto Inc. stock2025 Winners & Losers & Reliable Trade Execution Plans - DonanımHaber
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Galecto, Inc. announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Galecto (NASDAQ:GLTO) Price Target Raised to $36.00 at Guggenheim - Defense World
Finanzdaten der Galecto Inc-Aktie (GLTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):